[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-patients":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100593403","role-of-circulating-pyrophosphate-as-a-biomarker-of-mediacalcinosis-in-type-2-diabetic-patients-100593403",false,"NCT07005986","Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients","PPi-Diab","Inclusion Criteria:\n\n1. Adult men (between 40 and 70 years of age).\n2. T2DM defined according to ADA or HAS criteria, evolving for more than 6 months, may be : - Not complicated\n\n   * Complicated by diabetic retinopathy and\u002For diabetic nephropathy (creatinine clearance \\> 60 ml\u002Fmin) and\u002For peripheral arterial disease and\u002For ischemic heart disease and\u002For stroke. - With dyslipidemia (LDLc \\> 1.90) and\u002For a history of past or active smoking.\n   * Balanced with HbA1c \\\u003C 8% according to patient's personalized objectives, or unbalanced with HbA1c \\> 9%.\n   * Treated with insulin therapy (single or multi-injections) or not. - Whose treatment includes at least one iSGLT2.\n3. Member of 'Sécurité Sociale\"\n\nExclusion Criteria:\n\n1. Patient already included in another study.\n2. Patient in a particular situation judged incompatible with the study by the investigator.\n3. Patient living in a department other than Alpes-Maritimes or Var.\n4. Patient refusing to give consent.\n5. Patient deprived of liberty by administrative or judicial decision, under guardianship or curatorship.\n6. Patient with decompensated hepatic cirrhosis (Child C and above, score 10 to 15 points).\n7. Patients with chronic kidney disease (from stage 3, i.e. GFR \\\u003C 59 ml\u002Fmin\u002F1.73 m2).\n8. Patient with a recent fracture (within the last 3 months).\n9. Patient treated with AVK or biphosphonates.\n10. Patient with known, treated osteoporosis.\n11. Patient with unsupplemented vitamin D deficiency.\n12. Patient with active cancer.\n13. Patient with an active inflammatory pathology.","MALE","40 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Type 2 diabetes currently affects around 4 million people in France, with the number of cases rising steadily. Complications of T2DM are essentially cardiovascular. In particular, T2DM is associated with calcification of peripheral vessel walls (mediacalcosis), responsible for increased vascular stiffness. This calcium deposition is known to be a cardiovascular risk factor, but the mechanism of its deposition in relation to diabetes is not clearly established. An important blood compound, inorganic pyrophosphate (PPi), which is the body's natural anti-calcifier is impacted in some way in T2DM. PPi is degraded by alkaline phosphatase (ALP), and is produced by an enzyme called ENPP1. ENPP1 activity is decreased and APL activity increased in insulin-resistant subjects, which could contribute to a decrease in tissue and circulating PPi, and thus favor a tissue pro-calcifying balance. We propose to test this hypothesis in a pilot study characterizing plasma PPi levels, in relation to ENPP1 activity, in type 2 diabetic patients. The aim of the study is also to determine if there is a link between blood PPi levels and the progression of calcifications in arteries.",[27,28],"Type 2 Diabetes","Type 2 Diabetes Patients",[30],"Type 2 diabetes","RECRUITING","2025-07-09",{"date":34,"type":35},"2025-07-10","ACTUAL",{"date":37,"type":35},"2025-06-18",{"date":39,"type":21},"2026-07-18",{"name":41,"class":42},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100575222","the-effect-of-education-given-to-type-2-diabetics-on-diabetes-self-management-health-fatalism-and-metabolic-parameters-100575222","NCT06769477","The Effect of Education Given to Type 2 Diabetics on Diabetes Self-management, Health Fatalism and Metabolic Parameters","The Effect of Training With Motivational Interviewing Based on Health Belief Model on Diabetes Self-Management, Health Fatalism and Metabolic Parameters in Individuals With Type 2 Diabetes: A Randomized Controlled Experimental Study","Inclusion Criteria:\n\n* Having type 2 diabetes for at least 6 months\n* To be over 18 years old\n* Have sufficient communication skills to answer verbal and written questions and fulfill instructions\n* Becoming literate\n* No physical, cognitive or mental impairment in answering the questions\n* Willingness to participate in research.\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Being hospitalized in inpatient treatment institutions due to DM or DM complications during the research process\n* The emergence of any health problem that prevents the person from continuing the research\n* Do not leave the study voluntarily.",true,"ALL","18 Years",{"count":55,"type":21},66,[24],"This study aims to examine the effects on diabetes self-management, health fatalism and metabolic parameters of individuals with type 2 diabetes. The study will be conducted in a health institution between February 2025 and May 2025 and participants will be assigned to experimental and control groups by simple random sampling method. The experimental group will be trained with motivational interviewing techniques based on the health belief model for 8 weeks, followed by sending reminder SMS for 4 weeks. The control group will receive no intervention. The study is expected to improve the self-care behaviors of individuals with diabetes by creating positive effects on diabetes management and health fatalism.",[27,28],[60,61,62,63,64],"health belief model","motivational interview","self-management","health fatalism","type 2 diabetes","2025-02-23",{"date":67,"type":35},"2025-02-25",{"date":69,"type":35},"2025-02-01",{"date":71,"type":21},"2025-06-01",{"name":73,"class":42},"Ataturk University",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100292453","phase-4-liraglutide-bolus-vs-glargine-bolus-therapy-in-overweightobese-type-2-diabetes-patients-liragood-100292453","NCT03087032","Liraglutide-bolus vs Glargine-bolus Therapy in Overweight\u002FObese Type 2 Diabetes Patients (LiraGooD)","Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight \u002F Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study","LiraGooD","Inclusion Criteria:\n\n* Age: 18 - 75 years old.\n* BMI must be greater than 24 and less than 45 kg\u002Fm2\n* Patients with type 2 diabetes who met the World Health Organization (who) diagnostic criteria (1999).\n* Newly diagnosed type 2 diabetic patients with HbA1c ≥ 9.0%；or patients with uncontrolled type 2 diabetes (HbA1c ≥ 7.5% ) who have received at least two types of oral hypoglycemic drugs (the dose of each drug needs to reach the second largest dose or more), or only insulin (excluding basal-bolus insulin therapy), or insulin with oral hypoglycemic drugs.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* History of pancreatic disease,\n* History of medullary thyroid carcinoma\n* Lipase level \\> 3 times above normal,\n* Creatinine clearance ≤ 30 mL\u002Fmin\u002F1.73m2,\n* Evidence in the last 6 months of significant heart disease or stroke, including myocardial infarction, unstable angina, coronary bypass and\u002For percutaneous transluminal coronary angioplasty, congestive heart failure (New York Heart Association Functional Classification III-IV), or severe ischemic heart disease.\n* Preparation for pregnancy or having been in pregnancy\n* Researchers believe that there are any factors that affect assessing subjects' participation in trial.\n* Patients unable to cooperate in clinical trials","75 Years",{"count":85,"type":21},164,[87],"PHASE4","The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight \u002F obese patients with uncontrolled type 2 diabetes.",[28,90,91],"Overweight and Obesity","Hyperglycaemia (Diabetic)",[93,94,95],"Liraglutide","Insulin Glargine","Prandial Insulin","2025-01-09",{"date":98,"type":35},"2025-01-13",{"date":100,"type":35},"2019-01-10",{"date":102,"type":21},"2025-02-10",{"name":104,"class":42},"The First Affiliated Hospital of Xiamen University"]